JP2023551539A5 - - Google Patents
Info
- Publication number
- JP2023551539A5 JP2023551539A5 JP2023533236A JP2023533236A JP2023551539A5 JP 2023551539 A5 JP2023551539 A5 JP 2023551539A5 JP 2023533236 A JP2023533236 A JP 2023533236A JP 2023533236 A JP2023533236 A JP 2023533236A JP 2023551539 A5 JP2023551539 A5 JP 2023551539A5
- Authority
- JP
- Japan
- Prior art keywords
- bond
- peptide
- conjugate
- receptor
- conjugate according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063119555P | 2020-11-30 | 2020-11-30 | |
| US63/119,555 | 2020-11-30 | ||
| PCT/US2021/061186 WO2022115778A1 (en) | 2020-11-30 | 2021-11-30 | Radiopharmaceutical conjugate compositions and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023551539A JP2023551539A (ja) | 2023-12-08 |
| JP2023551539A5 true JP2023551539A5 (https=) | 2024-12-06 |
Family
ID=81753691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023533236A Pending JP2023551539A (ja) | 2020-11-30 | 2021-11-30 | 放射性医薬品コンジュゲート組成物及びその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230158179A1 (https=) |
| EP (1) | EP4251639A1 (https=) |
| JP (1) | JP2023551539A (https=) |
| CN (1) | CN116888138A (https=) |
| WO (1) | WO2022115778A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2023283882A1 (en) * | 2022-06-10 | 2025-01-30 | Peking University | Trifunctional compound and use thereof |
| WO2024041574A1 (en) * | 2022-08-24 | 2024-02-29 | Suzhou Transcenta Therapeutics Co., Ltd. | Non-invasive methods using anti-cldn18.2 antibody-radionuclide conjugates |
| CN117645652A (zh) * | 2022-09-02 | 2024-03-05 | 核欣(苏州)医药科技有限公司 | 环肽及其制备方法、包括其的复合物、及其用途 |
| PE20251640A1 (es) * | 2022-09-07 | 2025-06-24 | 3B Pharmaceuticals Gmbh | Ligandos de antigeno de membrana especifica de la prostata (psma) y uso de los mismos |
| WO2024073622A2 (en) * | 2022-09-29 | 2024-04-04 | Rayzebio, Inc. | Radiopharmaceutical compositions targeting ephrin type-a receptor 2 and uses thereof |
| JP2025532958A (ja) * | 2022-09-29 | 2025-10-03 | ペプチドリーム株式会社 | ＥｐｈＡ２結合保留ペプチド及びそれを含む組成物 |
| WO2024183634A1 (en) * | 2023-03-09 | 2024-09-12 | Norroy Bioscience Co., Ltd. | Radiolabeled antibody conjugates and uses thereof |
| JPWO2024195709A1 (https=) * | 2023-03-17 | 2024-09-26 | ||
| EP4692105A1 (en) * | 2023-03-27 | 2026-02-11 | Bivision Pharmaceuticals, Inc | Cyclic polypeptide compound and use thereof |
| WO2024198838A1 (zh) * | 2023-03-27 | 2024-10-03 | 晶核生物医药科技(南京)有限公司 | 环状多肽类化合物及其应用 |
| KR20260009883A (ko) * | 2023-05-24 | 2026-01-20 | 베이징 창핑 래보러토리 | 신규 삼관능 화합물 및 이의 용도 |
| AU2024282578A1 (en) * | 2023-05-31 | 2025-12-04 | Full-Life Technologies Uk Limited | Radioligands for targeting cell surface receptors and uses thereof |
| KR20260022328A (ko) * | 2023-06-07 | 2026-02-19 | 레이즈바이오, 인크. | 글리피칸-3을 표적화하는 방사성제약 조성물 및 그의 용도 |
| CN121712788A (zh) * | 2023-06-14 | 2026-03-20 | 马里亚纳肿瘤学公司 | 靶向dll3的肽及其构建体 |
| CN121712787A (zh) * | 2023-06-14 | 2026-03-20 | 马里亚纳肿瘤学公司 | 靶向dll3的肽及其构建体 |
| KR20260026051A (ko) * | 2023-06-14 | 2026-02-25 | 마리아나 온콜로지 인크. | Dll3 표적화 펩티드 및 이의 구성체 |
| AU2024326078A1 (en) * | 2023-08-15 | 2026-02-19 | Novartis Ag | Fap targeting cyclic peptides and conjugates thereof |
| TW202517674A (zh) | 2023-10-19 | 2025-05-01 | 德商拜耳廠股份有限公司 | 抗gpc3抗體及其放射性結合物 |
| WO2025117586A1 (en) * | 2023-11-27 | 2025-06-05 | Mariana Oncology Inc. | Dll3 targeting peptides and constructs thereof |
| WO2025137443A1 (en) | 2023-12-22 | 2025-06-26 | Rayzebio, Inc. | Radiopharmaceutical compositions targeting somatostatin receptors and uses thereof |
| WO2025179168A1 (en) * | 2024-02-22 | 2025-08-28 | Mariana Oncology Inc. | Synthesis of dll3-binding peptides |
| CN119119174B (zh) * | 2024-09-12 | 2025-08-08 | 重庆医科大学附属第二医院 | 一种靶向caix和fap的化合物、其核素标记物、制法和应用 |
| CN119874832A (zh) * | 2025-01-13 | 2025-04-25 | 重庆医科大学 | 一种新型多肽荧光探针的制备方法及应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6017512A (en) | 1992-06-23 | 2000-01-25 | Diatide, Inc. | Radiolabeled peptides |
| US5716596A (en) * | 1992-06-23 | 1998-02-10 | Diatide, Inc. | Radioactively labeled somatostatin-derived peptides for imaging and therapeutic uses |
| PL3152226T3 (pl) | 2014-06-06 | 2019-10-31 | Univ Muenchen Tech | Modyfikowane cyklopentapeptydy i ich zastosowania |
| US10421783B2 (en) * | 2016-02-19 | 2019-09-24 | The Curators Of The University Of Missouri | Prostate-specific membrane antigen (PSMA) targeting peptides |
| AU2017281940C1 (en) | 2016-06-24 | 2024-11-07 | University Of Iowa Research Foundation | Compositions and methods of treating melanoma |
| WO2020097531A1 (en) * | 2018-11-08 | 2020-05-14 | Indi Molecular, Inc. | Theranostic capture agents, compositions, and methods of using and making |
| JP7801207B2 (ja) * | 2019-07-08 | 2026-01-16 | ３ベー ファーマシューティカルズ ゲーエムベーハー | 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用 |
| FI3997103T3 (fi) * | 2019-07-08 | 2025-02-03 | 3B Pharmaceuticals Gmbh | Fibroblastien aktivaatioproteiinin ligandia käsittäviä yhdisteitä ja niiden käyttö |
-
2021
- 2021-11-30 WO PCT/US2021/061186 patent/WO2022115778A1/en not_active Ceased
- 2021-11-30 CN CN202180092527.XA patent/CN116888138A/zh active Pending
- 2021-11-30 EP EP21899224.6A patent/EP4251639A1/en active Pending
- 2021-11-30 JP JP2023533236A patent/JP2023551539A/ja active Pending
-
2022
- 2022-11-17 US US17/989,479 patent/US20230158179A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023551539A5 (https=) | ||
| JP7431261B2 (ja) | 自己安定化リンカー結合体 | |
| US20230340020A1 (en) | Peptide ligands for binding to mt1-mmp | |
| AU2024205105A1 (en) | Heterotandem bicyclic peptide complexes | |
| CA2965754C (en) | Bicyclic peptide ligands specific for mt1-mmp | |
| US8614290B2 (en) | Cancer imaging and treatment | |
| JP2015519339A5 (https=) | ||
| JP2021528434A (ja) | インテグリンαｖβ３に結合するためのペプチドリガンド | |
| TW201916894A (zh) | 自行穩定之接合劑共軛物 | |
| CN120865350A (zh) | 用于制备抗体-载荷部分偶联物的化合物及其用途 | |
| TWI838358B (zh) | 疏水性奧瑞他汀(auristatin)f化合物及其結合物 | |
| US20090069220A1 (en) | Dna-binding polyamide drug conjugates | |
| US8008316B2 (en) | Azonafide derived tumor and cancer targeting compounds | |
| CN111971060A (zh) | 募集抗体并靶向肿瘤细胞的双功能分子 | |
| WO2023179723A1 (zh) | 亲和片段导向的可裂解片段，其设计、合成及在制备定点药物偶联物中的应用 | |
| JP7356677B2 (ja) | 複合体 | |
| JP7221937B2 (ja) | 腫瘍標的化ペプチドバリアント | |
| EA045834B1 (ru) | Гетеротандемные бициклические пептидные комплексы | |
| Hudecz et al. | Peptide or protein based drug delivery and targeting systems | |
| Josephson et al. | Divergent Oriented Synthesis For the Design of Reagents for Protein Conjugation |